CooperCompanies Wraps Up Strategic Review, Boosts Buyback and Eyes Innovation with New R&D Hub

CooperCompanies (Nasdaq: COO) recently completed its strategic review, opting to retain its CooperSurgical unit and expanding its share repurchase authorization to $3 billion, while simultaneously planning a new global R&D hub—the Vision Centre—scheduled to open September 23, 2026.

Strategic Review Concludes with Retention of CooperSurgical

On September 9, 2026, CooperCompanies announced that its board of directors had unanimously decided to retain CooperSurgical rather than pursue a sale, following a rigorous strategic review initiated in December 2025. The board concluded that the offers received did not adequately reflect the business’s long-term value, given temporary market conditions such as Paragard competition and effects from a fertility litigation settlement.

This decision positions CooperCompanies to continue building value organically through CooperSurgical, particularly in fertility and women’s health.

Share Repurchase Authorization Increased to $3 Billion

Aligned with the company’s confidence in its cash generation and long-term strategy, CooperCompanies increased its share buyback authorization by $1 billion, bringing total capacity to $3 billion. This move underpins a continued focus on disciplined capital allocation and enhancing shareholder returns through repurchases—especially in the wake of generating record free cash flow in its recent quarter.

Innovation Accelerated with New Vision Centre

As part of a renewed growth strategy centered on innovation, CooperCompanies announced the opening of The Vision Centre, its new global research and development innovation hub for CooperVision, set for September 23, 2026. This investment signals a commitment to accelerated product development in the competitive contact lens space, complementing global commercial expansion efforts.

What It Means for Investors

The strategic review’s conclusion and expanded buyback pave a clearer path for capital return and a sharpened focus on organic growth, without the distraction or execution risk associated with a divestiture.

The Vision Centre underscores a long-term commitment to maintaining a leadership position in vision care through intensified R&D investment.

For investors, this combination of disciplined capital allocation, stronger governance, and innovation investment creates a cohesive framework aimed at sustainable growth and shareholder value enhancement in the quarters ahead.